Optimum treatment strategies for polyallergic patients – analysis of a large observational trial. (2nd December 2015)

• Record Type: Journal Article
• Authors: Shah-Hosseini, Kija; Mioc, Katharina; Hadler, Meike; Karagiannis, Efstrathios; Mösges, Ralph
• Is Part Of: Current medical research and opinion. Volume 31:Number 12(2015:Dec.)
• Page Start: 2249
• Page End: 2259
• Publication Date: 2015-12-02
• Subjects: Allergen immunotherapy -- Allergic rhinitis -- Polyallergy -- Polysensitization -- Subcutaneous immunotherapy -- Sublingual immunotherapy; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1185/03007995.2015.1094653
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objectives: To document the effectiveness and safety of sublingual allergen immunotherapy (SLIT) with a five-grass pollen tablet (Oralair * ) and compare different treatment options in a broad, non-selected population of patients in a real-world clinical setting. Research design and methods: This was a 2 year, open, prospective, multicenter, single-arm, non-interventional study. Patients with a history of clinically relevant allergic symptoms caused by grass pollen, confirmed by skin prick testing, received treatment with the five-grass pollen tablet. Concomitant treatment with symptomatic medication and/or additional SLIT or subcutaneous immunotherapy (SCIT) was permitted. Twelve-month data are presented here. Effectiveness was assessed comparing a combined rhinoconjunctivitis (RC) score derived from the severity of rhinitis and conjunctivitis symptoms under treatment with retrospective data of the previous year. Results: A total of 1408 patients participated in the study, of whom 434 were children/adolescents and 962 polyallergic. Compared with the grass pollen season preceding five-grass pollen tablet treatment, a statistically significant reduction of 49.9% was achieved in RC score for the total population ( p < 0.001), and an improvement in overall health was perceived by 90.9% of patients. The overall population of polyallergic patients derived similar benefits from treatment with the five-grass pollen tablet as monoallergic patients. The percentage reduction in RC score was larger in polyallergic patients taking no additional therapy (60.2%) than in those taking concomitant symptomatic medication (38.1%) or allergen immunotherapy (AIT) (50.8%). Within the last of these groups, RC score improved by 47.6% among patients receiving additional SCIT, versus 54.8% with additional SLIT. Adverse drug reactions, reported in 15.3% of study participants, were mostly local in nature and mild or moderate in intensity. Conclusions: After 1 year of treatment, polyallergic patients responded similarly to the five-grass pollen tablet as monoallergic patients. For polyallergic patients in whom additional treatment was needed, a second SLIT may be more beneficial than a SCIT or symptomatic co-medication.